| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Albendazole (formerly SKF-62979; SKF62979; SKF 62979; Zentel; Albenza; Eskazole; Valbazen), a benzimidazole analog and tubulin inhibitor, is an orally bioavailable anti-parasitic drug that has been approved for use in the treatment of various worm infestations such as giardiasis, neurocysticercosis, filariasis, hydatid disease, trichuriasis, pinworm disease, and ascariasis, among others. It acts as a tubulin inhibitor that binds to the colchicine-sensitive site of β-tubulin, thus inhibiting its polymerization or assembly into microtubules.
| ln Vitro |
In a dose-dependent manner, albendazole (100, 500, 1000 nM; 1, 3, or 5 days) inhibits the proliferation of cells[1]. SKHEP-1 cells are arrested by albendazole (100, 250, 500, 1000 nM; 3 days) at both the G0-G1 (250, 500 nM) and G2-M (1000 nM) phases of the cycle[1]. Albendazole (5 μM; 24, 36 h) primarily causes late apoptosis in HCT-1 16, HT29, and SW480 cells, along with time-dependent PARP and caspase-3 cleavage[2]. It also primarily causes early apoptosis in HCT-15 cells. In HCT-15, HCT-1 16, HT29, and SW480 cells, benendazole (5 μM; 24, 36 h) induces autophagy by upregulating the expression level of autophagy-related proteins (LC3, Atg7, p-beclin-1, and beclin-1)[2]. In A549 cells, albendazole (500 nM, 24 h) suppresses the expression of VEGF and HIF-1α induced by hypoxia[3].
|
|---|---|
| ln Vivo |
In mice, albendazole (10 mg/kg; ir; once daily for 30 days) decreases the weight of Echinococcus granulosus cysts[4]. ?For 20 days, albendazole (300 mg/kg; po; daily in two divided doses) significantly inhibits the formation of tumors in vivo[1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: SKHEP-1 cells Tested Concentrations: 100, 500, 1000 nM Incubation Duration: 1, 3, or 5 days Experimental Results: Inhibited cell proliferation in a dose-dependent manner. Cell Cycle Analysis[1] Cell Types: SKHEP-1 HCC cells Tested Concentrations: 100, 250, 500, 1000 nM Incubation Duration: 3 days Experimental Results: demonstrated dose-dependent effect on the cell cycle kinetics. Apoptosis Analysis[2] Cell Types: HCT-15, HCT-1 16, HT29, SW480 cells Tested Concentrations: 5 µM Incubation Duration: 24, 36 h Experimental Results: Promoted apoptosis in colon cancer cells. Cell Autophagy Assay[2] Cell Types: HCT -15, HCT-1 16, HT29, SW480 cells Tested Concentrations: 5 µM Incubation Duration: 24, 36 h Experimental Results: Induced autophagy in colon cancer cells. Western Blot Analysis[2] Cell Types: HCT-15, HCT-1 16, HT29, SW480 cells Tested Concentrations: 5 µM Incubation Duration: 12, 24, 36 h Experimental Results: Induced apoptosis-related protein (PARP, caspase-3) and autophagy-related protein (such as LC3, Atg7, p-beclin-1, and beclin-1) expression level in a time-dependent manner. In |
| Animal Protocol |
Animal/Disease Models: Female balb/c (Bagg ALBino) mouse (10-week-age; Echinococcus granulosus infection model)[4].
Doses: 10 mg/kg Route of Administration: po (oral gavage); one time/day for 30 days. Experimental Results: decreased Echinococcus granulosus cyst weights. Animal/Disease Models: Male BALB/c Nu/nu (nude) mice (6 to 10weeks old; inoculated subcutaneously (sc) with SKHEP-1)[1]. Doses: 50, 150, 300 mg/kg Route of Administration: Oral administration; per day in two divided dose for 20 days. Experimental Results: Profoundly suppressed tumor growth in vivo. |
| References |
[1]. Pourgholami MH, et al. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett. 2001 Apr 10;165(1):43-9.
[2]. Jung YY, et al. Regulation of apoptosis and autophagy by albendazole in human colon adenocarcinoma cells. Biochimie. 2022 Jul;198:155-166. [3]. Zhou F, et al. Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells. Mol Cell Biochem. 2017 Apr;428(1-2):171-178. [4]. Vural G, et al. Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice. Parasitology. 2020 Nov;147(13):1425-1432. [5]. Li L, et al. Determination of albendazole and metabolites in silkworm Bombyx mori hemolymph by ultrafast liquid chromatography tandem triple quadrupole mass spectrometry. PLoS One. 2014 Sep 25;9(9):e105637. |
| Molecular Formula |
C12H15N3O2S
|
|
|---|---|---|
| Molecular Weight |
265.33
|
|
| CAS # |
54965-21-8
|
|
| Related CAS # |
Albendazole sulfoxide;54029-12-8;Albendazole sulfoxide-d3;1448346-38-0;Albendazole-d3;1353867-92-1;Albendazole-d7;1287076-43-0
|
|
| SMILES |
S(C([H])([H])C([H])([H])C([H])([H])[H])C1C([H])=C([H])C2=C(C=1[H])N([H])C(N([H])C(=O)OC([H])([H])[H])=N2
|
|
| InChi Key |
HXHWSAZORRCQMX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
|
|
| Chemical Name |
methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (7.54 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (7.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7689 mL | 18.8445 mL | 37.6889 mL | |
| 5 mM | 0.7538 mL | 3.7689 mL | 7.5378 mL | |
| 10 mM | 0.3769 mL | 1.8844 mL | 3.7689 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA